Peter brings over 25 years’ experience in drug discovery across a range of therapeutic areas. Prior to joining Nimbus, he served as Vice President, Global Head of Lead Discovery at Janssen Pharmaceuticals. In this role, he led multiple aspects of discovery operations with teams located globally, working across multiple therapeutic areas. Prior to joining Janssen, he held leadership roles at GlaxoSmithKline, including Head of Biology for the Cancer Epigenetics Discovery Performance Unit, where his team progressed first-in-class epigenetic agents into oncology clinical trials against multiple novel targets. While at GSK, he contributed to the discovery and progression of several clinical candidates, including dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), which were approved for multiple oncology indications and daprodustat, which is completing Phase 3 clinical trials in chronic kidney disease. He also co-led GSK Oncology’s novel target selection effort. Earlier in his career he held scientific positions of increasing responsibility at Warner-Lambert/Parke-Davis, AstraZeneca, and Millennium Pharmaceuticals. He has published more than 80 peer-reviewed journal articles with greater than 12,000 citations. Peter earned his bachelor’s degree in chemistry from the University of Massachusetts and his PhD from the Department of Biological Chemistry at the University of Michigan. He completed a postdoctoral fellowship at Warner-Lambert/Parke-Davis.